Clinical Trial Update: Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 trial of five years of adjuvant imatinib mesylate (Gleevec) in patients with gastrointestinal stromal tumor (GIST). R…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumor (GIST) | Phase 2 | Status: COMPLETED | Results posted: 2018-03-14